WORLD-HEALTH-ORGANIZATION AND ERNATIONAL-LEAGUE-OF-ASSOCIATIONS-FOR-RHEUMATOLOGY CORE END-POINTS FOR SYMPTOM MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID-ARTHRITIS CLINICAL-TRIALS

Authors
BOERS M TUGWELL P FELSON DT VANRIEL PLCM KIRWAN JR EDMONDS JP SMOLEN JS KHALTAEV N MUIRDEN KD
Citation
M. Boers et al., WORLD-HEALTH-ORGANIZATION AND ERNATIONAL-LEAGUE-OF-ASSOCIATIONS-FOR-RHEUMATOLOGY CORE END-POINTS FOR SYMPTOM MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID-ARTHRITIS CLINICAL-TRIALS, Journal of rheumatology, 21, 1994, pp. 86-89
Citations number
25
Categorie Soggetti
Rheumatology
Journal title
Journal of rheumatology → ACNP
ISSN journal
0315162X
Volume
21
Year of publication
1994
Supplement
41
Pages
86 - 89
Database
ISI
SICI code
0315-162X(1994)21:<86:WAE>2.0.ZU;2-6
Abstract
The WHO/ILAR core set of endpoints for rheumatoid arthritis clinical t rials signifies progress in a continuing worldwide effort. This core s et includes the following measures: pain, patient global assessment, p hysical disability, swollen joints, tender joints, acute phase reactan ts, and physician global assessment; in studies of one or more years' duration, radiographs of joints should be performed.